PreprintCited by 897Epigenetics and DNA MethylationChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 64 of the 68 references it cites were found in a registry or an index.

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Open access

Tan, Jing, Yang, Xiaojing, Zhuang, Li, Jiang, Xia, Chen, Wei, Lee, Puay Leng, Karuturi, R.K. Murthy, Tan, Patrick Boon Ooi, Liu, Edison T., Yu, Qiang·2007·Genes & Development

DOI 10.1101/gad.1524107PMC PMC1855231

Open this paper in CoChat — free account Open PDF

Abstract

Polycomb-repressive complex 2 (PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy. Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells. We found that DZNep effectively depleted cellular levels of PRC2 components EZH2, SUZ12, and EED and inhibited associated histone H3 Lys 27 methylation (but not H3 Lys 9 methylation). By integrating RNA interference (RNAi), genome-wide expression analysis, and chromatin immunoprecipitation (ChIP) studies, we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep. We further demonstrate that the preferential reactivation of a set of these genes by DZNep, including a novel apoptosis affector, FBXO32 , contributes to DZNep-induced apoptosis in breast cancer cells. Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1524107

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1
Beisel, C., Imhof, A., Greene, J., Kremmer, E., & Sauer, F. (2002) · Nature · doi:10.1038/nature01126 · Cited by 310
Retracted
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 1×
“In contrast, histone H3 trimethylation at Lys 9 (H3-K9me3)—which is mediated by another histone MTase, Suv39h1 (Rea et al. 2000; Peters et al. 2001; Lehnertz et al. 2003)—was not affected by DZNep treatment.”
Background
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Polycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,568
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1279 · Cited by 2,404
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R., Chevalier, B. S., Johnstone, S. E., Cole, M. F., Isono, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,296
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204

Flagged first, then by citations

Show all 68 references

4 of the 68 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 897

Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy
Mann, M., Cortez, V. A., & Vadlamudi, R. K. (2011) · Cancers · doi:10.3390/cancers3021691 · Cited by 94
The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells
Yu, T., Wang, Y., Hu, Q., Wu, W., Wu, Y., Wei, W., Han, D., You, Y., Lin, N., & Liu, N. (2017) · Oncotarget · doi:10.18632/oncotarget.21311 · Cited by 99
Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Self-citation
EZH2 as a potential target in cancer therapy
McCabe, M. T., & Creasy, C. L. (2014) · Epigenomics · doi:10.2217/epi.14.23 · Cited by 91
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives
Sukocheva, O. A., Lukina, E., Friedemann, M., Menschikowski, M., Hagelgans, A., & Aliev, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.004 · Cited by 94
Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31
Zhang, Q., Padi, S. K. R., Tindall, D. J., & Guo, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.454 · Cited by 92
FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity
Mei, Z., Zhang, D., Hu, B., Wang, J., Shen, X., & Xiao, W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645978 · Cited by 88
Recent advances in SCF ubiquitin ligase complex: Clinical implications
Zheng, N., Zhou, Q., Wang, Z. P., & Wei, W. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.05.001 · Cited by 90
Emerging roles of F-box proteins in cancer drug resistance
Yan, L., Lin, M., Pan, S., Assaraf, Y. G., Wang, Z. P., & Zhu, X. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100673 · Cited by 85
Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Tian, X., Zhang, S., Liu, H., Zhang, Y., Blair, C., Mercola, D., Sassone‐Corsi, P., & Zi, X. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313050007 · Cited by 90
HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Self-citation
High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2
Coussens, N. P., Kales, S. C., Henderson, M. J., Lee, O. W., Horiuchi, K. Y., Wang, Y., Chen, Q., Kuznetsova, E., Wu, J., Chakka, S., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004274 · Cited by 87
Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
Kwon, M. J., Kim, S.-S., Choi, Y., Jung, H. S., Balch, C., Kim, S.-H., Song, Y. S., Márquez, V. E., Nephew, K. P., & Shin, Y. K. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp336 · Cited by 91
Post-translational modifications of EZH2 in cancer
Li, Z., Li, M., Wang, D., Hou, P., Chen, X., Chu, S., Chai, D., Zheng, J., & Bai, J. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00505-0 · Cited by 87
Targeting the enhancer of zeste homologue 2 in medulloblastoma
Alimova, I. N., Venkataraman, S., Harris, P. S., Márquez, V. E., Northcott, P. A., Dubuc, A. M., Taylor, M. D., Foreman, N. K., & Vibhakar, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27455 · Cited by 87
Polycomb Target Genes Are Silenced in Multiple Myeloma
Kalushkova, A., Fryknäs, M., Lemaire, M., Fristedt, C., Agarwal, P., Eriksson, M., Deleu, S., Atadja, P. W., Österborg, A., Nilsson, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011483 · Cited by 87
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Curry, E. W., Green, I., Chapman‐Rothe, N., Shamsaei, E., Kandil, S., Cherblanc, F., Payne, L., Bell, E., Ganesh, T., Srimongkolpithak, N., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0118-9 · Cited by 91
Corepressor Protein CDYL Functions as a Molecular Bridge between Polycomb Repressor Complex 2 and Repressive Chromatin Mark Trimethylated Histone Lysine 27
Zhang, Y., Yang, X., Gui, B., Xie, G., Zhang, D., Shang, Y., & Liang, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271064 · Cited by 89
Self-citation
Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation
Feng, M., Li, Z., Aau, M., Wong, C., Yang, X., & Yu, Q. (2011) · Oncogene · doi:10.1038/onc.2010.602 · Cited by 85
Self-citation
Multifaceted role of EZH2 in breast and prostate tumorigenesis
Deb, G., Thakur, V. S., & Gupta, S. (2013) · Epigenetics · doi:10.4161/epi.24532 · Cited by 92
Polycomb genes and cancer: Time for clinical application?
Crea, F., Paolicchi, E., Márquez, V. E., & Danesi, R. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.10.007 · Cited by 87
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells
Lee, J.-K., & Kim, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.128 · Cited by 84
Ibf1 and Ibf2 are novel CP190‐interacting proteins required for insulator function
Cuartero, S., Frésán, U., Reina, O., Planet, E., & Espinàs, M. (2014) · EMBO Journal · doi:10.1002/embj.201386001 · Cited by 68
Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development
Ramming, A., Druzd, D., Leipe, J., Schulze‐Koops, H., & Skapenko, A. (2012) · Blood · doi:10.1182/blood-2011-11-392589 · Cited by 89
In Vivo Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder Cancer
Santos, M., Martínez‐Fernández, M., Dueñas, M., García‐Escudero, R., Alfaya, B., Villacampa, F., Sáiz-Ladera, C., Costa, C., Oteo, M., Duarte, J. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1218 · Cited by 84
TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Cheng, L. L., Itahana, Y., Lei, Z. D., Chia, N., Wu, Y., Yu, Y., Zhang, S. L., Thike, A. A., Pandey, A., Rozen, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0036 · Cited by 89
Self-citation
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
Yu, J., Cao, Q., Yu, J., Wu, L., Dallol, A., Li, J., Chen, G., Grasso, C. S., Cao, X., Lonigro, R. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.269 · Cited by 84
Targeting histone methyltransferase EZH2 as cancer treatment
Kondo, Y. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu054 · Cited by 82
TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation
Li, J.-D., Xi, Y., Li, W., McCarthy, R. L., Stratton, S. A., Zou, W., Li, W., Dent, S., Jain, A. K., & Barton, M. C. (2017) · Oncogene · doi:10.1038/onc.2016.453 · Cited by 81
EZH2 regulates spinal neuroinflammation in rats with neuropathic pain
Yadav, R., & Weng, H.-R. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.02.041 · Cited by 78
Pulsed immune reconstitution therapy in multiple sclerosis
Sørensen, P. S., & Sellebjerg, F. T. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419836913 · Cited by 82
3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells
Girard, N., Bazille, C., Lhuissier, E., Bénateau, H., Llombart‐Bosch, A., Boumédiene, K., & Baugé, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098176 · Cited by 93
Cancer Epigenetics: New Therapies and New Challenges
Hatzimichael, E. C., & Crook, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/529312 · Cited by 85
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP
Zhang, X., Schulz‐Heddergott, R., Edmunds, S. J., Krüger, E., Markert, E. K., Gaedcke, J., Cormet‐Boyaka, E., Ghadimi, M. B., Beißbarth, T., Levine, A. J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.036 · Cited by 78
EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications
Li, Z., Takenobu, H., Setyawati, A. N., Akita, N., Haruta, M., Satoh, S., Shinno, Y., Chikaraishi, K., Mukae, K., Akter, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0133-3 · Cited by 79
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
Abdel-Hafiz, H. A. (2017) · Diseases · doi:10.3390/diseases5030016 · Cited by 84
The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
Li, Z., Wang, Y., Qiu, J., Li, Q., Yuan, C., Zhang, W., Wang, D., Ye, J., Jiang, H., Yang, J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1503 · Cited by 79
EZH2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis
Zhao, Y., Ding, L., Wang, D., Ye, Z., He, Y., Ma, L., Zhu, R., Pan, Y., Wu, Q., Pang, K., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201899599 · Cited by 81
EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Kang, N., Eccleston, M., Clermont, P., Latarani, M., Male, D. K., Wang, Y. Z., & Crea, F. (2020) · Epigenomics · doi:10.2217/epi-2020-0186 · Cited by 79
Epigenetic Regulation of Cancer-Associated Genes in Ovarian Cancer
Kwon, M. J., & Shin, Y. K. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12020983 · Cited by 79
Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements
Tonini, T., D’Andrilli, G., Fucito, A., Gaspa, L., & Bagella, L. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21241 · Cited by 75
Mechanisms of Yin Yang 1 in Oncogenesis: The Importance of Indirect Effects
Atchison, M. L., Basu, A., Zápražná, K., & Papasani, M. R. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i3-4.20 · Cited by 74
Epigenetic regulation of endothelial‐cell‐mediated vascular repair
Fraineau, S., Palii, C. G., Allan, D., & Brand, M. (2014) · FEBS Journal · doi:10.1111/febs.13183 · Cited by 80
Targeting epigenetic regulations in cancer
Ning, B., Li, W., Zhao, W., & Wang, R. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv116 · Cited by 77
Epigenetic cancer therapy: Proof of concept and remaining challenges
Mund, C., & Lyko, F. (2010) · BioEssays · doi:10.1002/bies.201000061 · Cited by 77
Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
Momparler, R. L., Côté, S., Momparler, L. F., & Idaghdour, Y. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-19 · Cited by 75
Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancerThis paper is one of a selection of papers published in this Special Issue, entitled The 30th Annual International Asilomar Chromatin and Chromosomes Conference, and has undergone the Journal's usual peer review process.
Gieni, R. S., & Hendzel, M. J. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-057 · Cited by 76
EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
Paskeh, M. D. A., Mehrabi, A., Gholami, M. H., Zabolian, A., Ranjbar, E., Saleki, H., Ranjbar, A., Hashemi, M., Ertaş, Y. N., Hushmandi, K., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112532 · Cited by 74
DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma
Bennett, L. B., Schnabel, J. L., Kelchen, J. M., Taylor, K. H., Guo, J., Arthur, G. L., Papageorgio, C., Shi, H., & Caldwell, C. W. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20687 · Cited by 74
Enhancer of Zeste Homolog 2 Overexpression Has a Role in the Development of Anaplastic Thyroid Carcinomas
Borbone, E., Troncone, G., Ferraro, A., Jasencakova, Z., Stojic, L., Esposito, F., Hornig, N., Fusco, A., & Orlando, V. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1784 · Cited by 77
Epigenetic Factors in Cancer Development: Polycomb Group Proteins
Piunti, A., & Pasini, D. (2010) · Future Oncology · doi:10.2217/fon.10.157 · Cited by 76
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors
Bommi, P. V., Dimri, M., Sahasrabuddhe, A. A., Khandekar, J. D., & Dimri, G. P. (2010) · Cell Cycle · doi:10.4161/cc.9.13.12147 · Cited by 73
The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD)
Sarmento, O. F., Svingen, P. A., Xiong, Y., Sun, Z., Bamidele, A. O., Mathison, A., Smyrk, T. C., Nair, A., Gonzalez, M. M., Sagstetter, M. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.749663 · Cited by 73
Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer
Worku, T., Bhattarai, D., Ayers, D., Wang, K., Wang, C., Rehman, Z. U., Talpur, H. S., & Yang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485395 · Cited by 72
The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells
Wagener, N., Holland, D., Bulkescher, J., Crnković‐Mertens, I., Hoppe‐Seyler, K., Zentgraf, H., Pritsch, M., Buse, S., Pfitzenmaier, J., Haferkamp, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23683 · Cited by 74
The biology of lysine acetylation integrates transcriptional programming and metabolism
Patel, J. A., Pathak, R. R., & Mujtaba, S. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-12 · Cited by 76
Drosophila HP1c isoform interacts with the zinc-finger proteins WOC and Relative-of-WOC to regulate gene expressionPreprint
Font-Burgada, J., Rossell, D., Auer, H., & Azorı́n, F. (2008) · Genes & Development · doi:10.1101/gad.481408 · Cited by 72
Quantitative Nuclear Proteomics Identifies that miR-137-mediated EZH2 Reduction Regulates Resveratrol-induced Apoptosis of Neuroblastoma Cells*
Ren, X., Bai, X., Zhang, X., Li, Z., Tang, L., Zhao, X., Li, Z., Ren, Y., Wei, S., Wang, Q., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.041905 · Cited by 71
Regulation of the Polycomb protein RING1B ubiquitination by USP7
de Bie, P., Zaaroor-Regev, D., & Ciechanover, A. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.082 · Cited by 71
Structure of the PRC2 complex and application to drug discovery
Shi, Y., Wang, X., Zhuang, Y., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.7 · Cited by 75
The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma
Rajan, P. K., Udoh, U. S., Sanabria, J. D., Banerjee, M., Smith, G., Schade, M. S., Sanabria, J. A., Sodhi, K., Pierre, S. V., Xie, Z., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238894 · Cited by 72
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia
Zhou, J. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i4.473 · Cited by 74
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
Ciarapica, R., Carcarino, E., Adesso, L., Salvo, M. D., Bracaglia, G., Leoncini, P. P., Dall’Agnese, A., Verginelli, F., Milano, G. M., Boldrini, R., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-139 · Cited by 72
Cancer Epigenetics for the 21st Century: What's Next?
Esteller, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423096 · Cited by 71
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W. M., Sleijfer, S., Foekens, J. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1877-4 · Cited by 70
Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer
Liu, Q., Wang, G., Li, Q., Jiang, W., Kim, J., Wang, R., Zhu, S. L., Wang, X., Lin, Y., Yang, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32118 · Cited by 69
Histone Modification Therapy of Cancer
Biancotto, C., Frigè, G., & Minucci, S. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60013-7 · Cited by 74
The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)
Ciarapica, R., Salvo, M. D., Carcarino, E., Bracaglia, G., Adesso, L., Leoncini, P. P., Dall’Agnese, A., Walters, Z. S., Verginelli, F., Sio, L. D., et al. (2013) · Oncogene · doi:10.1038/onc.2013.471 · Cited by 70
Self-citation
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Sun, F., Chan, E., Wu, Z., Yang, X., Márquez, V. E., & Yu, Q. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0479 · Cited by 69
Self-citation
Cancer Stem Cell Epigenetics And Chemoresistance
Crea, F., Danesi, R., & Farrar, W. L. (2009) · Epigenomics · doi:10.2217/epi.09.4 · Cited by 70
EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival
Smits, M., van Rijn, S., Hulleman, E., Biesmans, D., van Vuurden, D. G., Kool, M., Haberler, C., Aronica, E., Vandertop, W. P., Noske, D. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0399 · Cited by 68
EZH2 in Bladder Cancer, a Promising Therapeutic Target
Martínez‐Fernández, M., Rubio, C., Segovia, C., López-Calderón, F., Dueñas, M., & Paramio, J. M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126000 · Cited by 68
Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells
He, S., Wang, J., Kato, K., Xie, F., Varambally, S., Mineishi, S., Kuick, R. D., Mochizuki, K., Liu, Y., Nieves, E. C., et al. (2011) · Blood · doi:10.1182/blood-2011-06-364422 · Cited by 70
Cladribine: not just another purine analogue?
Spurgeon, S. E. F., Yu, M. K., Phillips, J. D., & Epner, E. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903071038 · Cited by 68
3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
Ni, J., Hou, X., Wang, X., Shi, Y., Xu, L., Zheng, X., Liu, N., Qiu, A., & Zhuang, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1589-y · Cited by 69
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease
He, S., Xie, F., Liu, Y., Tong, Q., Mochizuki, K., Lapinski, P. E., Mani, R. S., Reddy, P. R., Mochizuki, I., Chinnaiyan, A. M., et al. (2013) · Blood · doi:10.1182/blood-2013-05-505180 · Cited by 67
EZH2 Modulates Angiogenesis In Vitro and in a Mouse Model of Limb Ischemia
Mitić, T., Caporali, A., Floris, I., Meloni, M., Marchetti, M., Urrutia, R. A., Angelini, G. D., & Emanueli, C. (2014) · Molecular Therapy · doi:10.1038/mt.2014.163 · Cited by 67
EZH2, a Potential Regulator of Dental Pulp Inflammation and Regeneration
Hui, T., Peng, A., Zhao, Y., Wang, C., Gao, B., Zhang, P., Wang, J., Zhou, X., & Ye, L. (2014) · Journal of Endodontics · doi:10.1016/j.joen.2014.01.031 · Cited by 67
Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas
Kleb, B., Estecio, M. R., Zhang, J., Tzelepi, V., Chung, W., Jelı́nek, J., Navone, N. M., Tahir, S. A., Márquez, V. E., Issa, J. J., et al. (2016) · Epigenetics · doi:10.1080/15592294.2016.1146851 · Cited by 68
Combined inhibition of EZH 2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells
Takashina, T., Kinoshita, I., Kikuchi, J., Shimizu, Y., Sakakibara‐Konishi, J., Oizumi, S., Nishimura, M., & Dosaka‐Akita, H. (2016) · Cancer Science · doi:10.1111/cas.12957 · Cited by 70
H3K27 Methylation
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 75
Molecular mechanisms and therapeutic targets in pediatric brain tumors
Liu, K.-W., Pajtler, K. W., Worst, B. C., Pfister, S. M., & Wechsler‐Reya, R. J. (2017) · Science Signaling · doi:10.1126/scisignal.aaf7593 · Cited by 67
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 68
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis
Jiang, T., Wang, Y., Zhou, F., Gao, G., Ren, S., & Zhou, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6612 · Cited by 68
EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial–Mesenchymal Transition and anoikis in colon cancer cells
Ferraro, A., Mourtzoukou, D., Kosmidou, V., Avlonitis, S., Kontogeorgos, G., Zografos, G., & Pintzas, A. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.10.009 · Cited by 69
Sulforaphane Suppresses Polycomb Group Protein Level via a Proteasome-Dependent Mechanism in Skin Cancer Cells
Balasubramanian, S., Chew, Y. C., & Eckert, R. L. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072363 · Cited by 66
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 71
Polycomb proteins in hematologic malignancies
Martin-Perez, D., Piris, M. A., & Sanchez-Beato, M. (2010) · Blood · doi:10.1182/blood-2010-05-267096 · Cited by 65
Chemical and biochemical approaches in the study of histone methylation and demethylation
Li, K. K., Luo, C., Wang, D., Jiang, H., & Zheng, Y. G. (2010) · Medicinal Research Reviews · doi:10.1002/mrr.20228 · Cited by 73
Targeting EZH2 for Cancer Therapy: Progress and Perspective
Li, C. H., & Chen, Y. (2015) · Current Protein and Peptide Science · doi:10.2174/1389203716666150409100233 · Cited by 63
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 68
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers
Au, S. L., Wong, C. C., Lee, J. M., Wong, C., & Ng, I. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068226 · Cited by 67
The Link Between Hyperhomocysteinemia and Hypomethylation
Barroso, M., Handy, D. E., & Castro, R. (2017) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409817698994 · Cited by 63
Role of H3K27 Demethylases Jmjd3 and UTX in Transcriptional RegulationPreprint
Hübner, M. R., & Spector, D. L. (2010) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2010.75.020 · Cited by 65
Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma
Colyn, L., Bárcena‐Varela, M., Álvarez‐Sola, G., Latasa, M. U., Uriarte, I., Santamaría, E., Herranz, J. M., Santos‐Laso, Á., Arechederra, M., de Gauna, M. R., et al. (2020) · Hepatology · doi:10.1002/hep.31642 · Cited by 62
Targeting the epigenome for treatment of cancer
Geutjes, E.-J., Bajpe, P. K., & Bernards, R. (2011) · Oncogene · doi:10.1038/onc.2011.552 · Cited by 62
Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid‐induced apoptosis through down‐regulation of EZH 2 expression by miR ‐101
Wang, Y., Xiang, W., Wang, M., Huang, T., Xiao, X., Wang, L., Tao, D., Dong, L., Zeng, F., & Jiang, G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12501 · Cited by 61
Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus
Ochiai (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.868 · Cited by 62
EZH2 Regulates Cofilin Activity and Colon Cancer Cell Migration by Targeting ITGA2 Gene
Ferraro, A., Boni, T., & Pintzas, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115276 · Cited by 61
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma
Anestopoulos, I., Sfakianos, A., Franco, R., Chlichlia, K., Panayiotidis, M. I., Kroll, D. J., & Pappa, A. (2016) · Molecules · doi:10.3390/molecules22010062 · Cited by 61

Authors: Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q.
Affiliations: Genome Institute of Singapore (SG)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Duke-NUS Medical School (SG)
ORCID: Tan, Jing
Yang, Xiaojing
Zhuang, Li
Jiang, Xia
Chen, Wei
Lee, Puay Leng
Karuturi, R.K. Murthy
Liu, Edison T.
Yu, Qiang
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2007-04-16
Volume: 21
Issue: 9
Pages: 1050-1063
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1524107
PMC: PMC1855231
OpenAlex: W2113634596
Cited by: 895
References: 68
Citations by year: 2026: 12 · 2025: 16 · 2024: 18 · 2023: 35 · 2022: 21 · 2021: 35 · 2020: 39 · 2019: 37 · 2018: 44 · 2017: 65 · 2016: 55 · 2015: 65 · 2014: 98 · 2013: 77 · 2012: 70
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
Funders: Agency for Science, Technology and Research
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: polycomb repressive complex 2, DZNep, EZH2, SUZ12, EED, histone H3 lysine 27 methylation, gene silencing, apoptosis, breast cancer, atrogin-1, chromatin remodeling, cancer therapy
MeSH terms: Adenosine, Base Sequence, Breast Neoplasms, Enzyme Inhibitors, Female, Histones, Humans, Methylation, Promoter Regions, Genetic, Repressor Proteins, RNA Polymerase II, Apoptosis, RNA Interference, RNA, Small Interfering, Chromatin Assembly and Disassembly, Adenosylhomocysteinase, Epigenesis, Genetic, Cell Line, Tumor, Chromatin Immunoprecipitation, Polycomb-Group Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks